20 Nov 2026 09:55 10:20
Interstitial lung abnormalities (ILAs) are chest CT findings suggestive of interstitial lung disease (ILD) in people without a clinical diagnosis of ILD. With lung cancer screening and the wide use of CT, they are increasingly encountered in respiratory practice. The 2025 American Thoracic Society (ATS) clinical statement updated the 2020 Fleischner Society definition: ILA is now defined as bilateral, nondependent ground-glass or reticular abnormalities, lung distortion, traction bronchiectasis, or honeycombing involving at least 5% of a lung zone, without the requirement that the findings be incidental, and with high-risk groups such as familial pulmonary fibrosis and connective tissue disease included. A working definition separates ILA from ILD on the basis of symptoms, physiology, imaging, and pathology.
ILA is found in about 3–10% of older adults and 4–17% of smokers. Risk factors include older age, male sex, smoking, occupational and environmental exposures, the MUC5B promoter variant, short telomeres, and a family history of pulmonary fibrosis. ILA is associated with respiratory symptoms, reduced exercise capacity, lung cancer, complications of cancer treatment and surgery, acute respiratory distress syndrome, and all-cause mortality. About half of ILAs progress radiologically, and subpleural fibrotic ILA, reticulation, and traction bronchiectasis carry the highest risk of progression and death.
Based on 11 questions, the ATS statement suggests systematic assessment of ILA on lung cancer screening CT, baseline CT for adults with connective tissue disease at risk of ILD and for first-degree relatives older than 50 years in familial pulmonary fibrosis, assessment of symptoms and lung function at baseline, and serial CT timed by risk; it suggests against lung biopsy and routine MUC5B or telomere testing. Risk reduction, including smoking cessation and exposure remediation, is recommended throughout. No pharmacological treatment is currently recommended for ILA, but prevention trials with better-tolerated antifibrotics, such as DROP-FPF with nerandomilast, have begun. This lecture reviews the definition, epidemiology, clinical significance, risk assessment, and management of ILA, with data from Korean cohorts.